Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment

BACKGROUND: Cholinesterase inhibitors (ChEIs) are an FDA-approved symptomatic treatment for patients with Alzheimer’s disease (AD). Its efficacy in patients with mild cognitive impairment (MCI), however, is controversial. Nonetheless, ChEIs have often been used in patients with MCI. From the perspec...

Descripción completa

Detalles Bibliográficos
Autores principales: Pyun, Jung-Min, Ryoo, Nayoung, Park, Young Ho, Kim, SangYun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786503/
https://www.ncbi.nlm.nih.gov/pubmed/33402198
http://dx.doi.org/10.1186/s13195-020-00749-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786503/
https://www.ncbi.nlm.nih.gov/pubmed/33402198
http://dx.doi.org/10.1186/s13195-020-00749-5

Ejemplares similares